Depression, anxiety common in men with pelvic pain
May 1st 2005Istanbul, Turkey--Chronic prostatitis appears to be significantly associated with psychological disorders, such as depression, anxiety, and panic, according to the results of a German study. The study also found that pelvic pain symptoms are far less prevalent than expected (3.2%), while the mean age of afflicted men was significantly higher than noted in previous trials (60.6 years).
TUMT shows durable results in chronic prostatitis
May 1st 2005Istanbul, Turkey--Transurethral microwave thermotherapy of the prostate offers a 50% improvement in pain in up to two-thirds of patients with chronic prostatitis/chronic pelvic pain syndrome, which is comparable to other treatment modalities, according to researcher Christof Kastner, MD, PhD. The therapy also appears to promise good durability 2 years post-procedure.
Biofeedback physical therapy improves CPPS symptoms
May 1st 2005Istanbul, Turkey--Biofeedback physical therapy and pelvic floor re-education appear to offer symptomatic improvement in men with chronic pelvic pain syndrome type III, Dutch researchers say. The techniques appear to work by improving relaxation and demonstrating proper use of pelvic floor muscles.
Testicular cancer treatment impairs semen quality
January 1st 2005Philadelphia--Treatment for testicular cancer caused the rates of severe oligozoospermia and azoospermia to rise from 7% to 27% and 0% to 12%, respectively, in a study that suggests a need for sperm banking in men treated for the disease.
Guidelines advise on thrombotic events in urology
January 1st 2005Toronto--Although few published studies exist on the prevention of thromboembolic disorders in urologic surgery, the risk of such disorders appears to be similar to that seen in other major surgical procedures.Therefore, urologists should concentrate on identifying patients at sufficient risk to warrant routine thromboprophylaxis, said the co-author of a new set of antithrombotic guidelines from the American College of Chest Physicians.
Frozen, fresh sperm show similar fertilization rates
January 1st 2005Philadelphia--A new study shows that fertilization rates with cryopreserved sperm are not inferior to those with "fresh" sperm, although it will be several more years before researchers can determine whether the rates are equal in nature.
Sperm concentration, motility decrease as men age
December 1st 2004Caxias do Sul, Brazil--Men over the age of 40 years may have lower semen quality, but not necessarily lower sperm morphology. That's an important fact to remember when evaluating these men for infertility, suggests a study by Brazilian researchers.
Definition of interstitial cystitis still controversial
December 1st 2004Interstitial cystitis is not an uncommon condition, yet researchers continue in their struggle to define it and reach consensus on appropriate diagnostic criteria. In part one of this two-part Urology Times interview, Christopher K. Payne, MD, discusses the current controversy over the definition of IC and his approach to diagnosis.
Definition of interstitial cystitis still controversial
December 1st 2004Interstitial cystitis is not an uncommon condition, yet researchers continue in their struggle to define it and reach consensus on appropriate diagnostic criteria. In part one of this two-part Urology Times interview, Christopher K. Payne, MD, discusses the current controversy over the definition of IC and his approach to diagnosis.
Oral agent shows durable improvement in SUI patients
November 1st 2004San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.
Existing anticholinergics show few CNS effects
November 1st 2004San Diego-Two anticholinergic drugs commonly used in the treatment of overactive bladder have similarly low incidences of adverse events affecting the central nervous system, according to an analysis of data from a large randomized trial of the agents.
Oral agent shows durable improvement in SUI patients
November 1st 2004San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.
Newer bulking agent offers durable results in SUI
October 15th 2004San Diego-A newer bulking agent consisting of synthetic calcium hydroxylapatite compares favorably with traditional glutaraldehyde cross-linked bovine collagen as a treatment for type III stress urinary incontinence or intrinsic sphincteric deficiency, according to an interim analysis of data from an ongoing randomized trial of the two substances.
Nearly one in four older women report incontinence
October 1st 2004San Francisco--Urinary incontinence remains a common medical condition in older women, even in those who rate their health as "good" or "excellent." Nearly 12% of elderly women experience stress, urge, or other form of incontinence, according to findings from an analysis of the Health, Aging, and Body Composition study published in Obstetrics & Gynecology (2004; 104:301-7). The condition is more prevalent in Caucasian women than in African-Americans, the study found.
Nearly one in four older women report incontinence
October 1st 2004San Francisco--Urinary incontinence remains a common medical condition in older women, even in those who rate their health as "good" or "excellent." Nearly 12% of elderly women experience stress, urge, or other form of incontinence, according to findings from an analysis of the Health, Aging, and Body Composition study published in Obstetrics & Gynecology (2004; 104:301-7). The condition is more prevalent in Caucasian women than in African-Americans, the study found.
Short-term androgen therapy plus RT boosts survival
October 1st 2004A 6-month course of androgen suppression therapy following radiation treatment for clinically localized prostate cancer confers survival benefits similar to those seen with longer courses of androgen blockade (>3 years), according to a recent study from Brigham and Women's Hospital and the Dana Farber Cancer Institute, Boston. The study also suggests that only partial blockade with a luteinizing hormone-releasing hormone (LHRH) agonist may be sufficient.